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OBJECTIVE—To assess whether the detection of enterovirus
RNA in blood predicts the development of clinical type 1 diabetes
in a prospective birth cohort study. Further, to study the role of
enteroviruses in both the initiation of the process and the
progression to type 1 diabetes.
RESEARCH DESIGN AND METHODS—This was a nested
case-control study where all case children (N  38) have
progressed to clinical type 1 diabetes. Nondiabetic control chil-
dren (N  140) were pairwise matched for sex, date of birth,
hospital district, and HLA-DQ–conferred genetic susceptibility to
type 1 diabetes. Serum samples, drawn at 3- to 12-month inter-
vals, were screened for enterovirus RNA using RT-PCR.
RESULTS—Enterovirus RNA–positive samples were more fre-
quent among the case subjects than among the control subjects.
A total of 5.1% of the samples (17 of 333) in the case group were
enterovirus RNA–positive compared with 1.9% of the samples (19
of 993) in the control group (P  0.01). The strongest risk for
type 1 diabetes was related to enterovirus RNA positivity during
the 6-month period preceding the ﬁrst autoantibody-positive
sample (odds ratio 7.7 [95% CI 1.9–31.5]). This risk effect was
stronger in boys than in girls.
CONCLUSIONS—The present study supports the hypothesis
that enteroviruses play a role in the pathogenesis of type 1
diabetes, especially in the initiation of the -cell damaging
process. The enterovirus-associated risk for type 1 diabetes may
be stronger in boys than in girls. Diabetes 60:276–279, 2011
E
nterovirus infections are among the major can-
didates for environmental risk factors for type 1
diabetes. Previous studies have suggested that
enterovirus epidemics associate with an in-
crease in the incidence of type 1 diabetes, and an in-
creased frequency of enterovirus antibodies has been
reported in patients with type 1 diabetes (1,2). Several
studies have detected enterovirus genome in the blood of
diabetic patients, but it is unknown whether the ﬁnding
reﬂects persistent or acute infection (3). Virus has been
detected both in pancreas and in intestinal mucosa and
has also shown a tropism for islets (4,5). On some occa-
sions, coxsackievirus B and echoviruses have even been
isolated from diabetic children (6). The recent discovery
that genetic polymorphism in the IFIH1 gene (innate
immune system sensor for enteroviruses) affects diabetes
susceptibility has further supported the possible role of
enteroviruses (7). Experimental data support these ﬁnd-
ings because enteroviruses can cause diabetes in mice and
damage -cells in human islet cell cultures in vitro (3).
Type 1 diabetes–associated autoantibodies in peripheral
blood reﬂect initiation of the -cell–damaging processes.
However, the progression toward clinical diabetes is usu-
ally slow, and possible triggering infections can occur long
before the presentation of clinical type 1 diabetes. Conse-
quently, prospective follow-up series are essential for the
identiﬁcation of such triggers. A few prospective studies
have been carried out on the possible role of enterovirus
infections, but the results have been conﬂicting (8–11).
The aim of this study is to test risk effect of enterovirus
RNA in blood for the development of type 1 diabetes in a
prospective birth cohort study. Blood samples were col-
lected with short intervals, which made it possible to
detect enterovirus RNA directly from the serum in differ-
ent stages of the disease process. We have previously
documented the risk effect of enteroviruses in children
who developed -cell autoimmunity. Now, the aim is to
conﬁrm these ﬁndings in children who have developed
type 1 diabetes and to study the role of these viruses in
both the initiation of the process and its progression to
diabetes.
RESEARCH DESIGN AND METHODS
Study series. The study series included children who took part in the Finnish
type 1 Diabetes Prediction and Prevention (DIPP) study (12). In DIPP, the
families of all newborn infants at the University Hospitals of Oulu, Tampere,
and Turku are offered a possibility for screening of newborn infants for HLA
risk genes for type 1 diabetes. Families with a child who carries increased
genetic susceptibility to diabetes are invited to participate in prospective
follow-up starting from birth. Blood samples are taken in 3- to 12-month
intervals and regularly analyzed for type 1 diabetes–associated autoantibod-
ies. Islet cell antibodies (ICAs) have been used for the primary screening, and
all samples of ICA-positive children were tested for autoantibodies against
insulin (IAA), glutamate decarboxylase (GADA), and the protein tyrosine
phosphatase–related islet antigen 2 (IA-2A). Children who seroconverted to
autoantibody positivity were observed subsequently at an interval of 3
months.
The current study is based on a nested case-control design, where the
deﬁnition of the case status was based on the diagnosis of clinical type 1
diabetes. For every case child, one to six healthy autoantibody-negative
control children were matched pairwise for sex, date of birth (1 month),
hospital district, and HLA-DQ–conferred genetic susceptibility to type 1
diabetes. The study population comprised a total of 38 case children (18 boys)
and 140 control children (69 boys). Serum samples were collected for virus
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276 DIABETES, VOL. 60, JANUARY 2011 diabetes.diabetesjournals.organalyses from November 1994 to April 2003, and the total number of samples
analyzed was 1,326. Our earlier study population overlaps with the current
study, with 129 samples from 21 case children and 474 samples from 85
control children (11).
The study was approved by the ethics committees of the participating
university hospitals. Parents gave written informed consent.
Genetic and autoantibody analyses. The presence of HLA DR-DQ haplo-
type associated with type 1 diabetes was determined using typing for DQB1
alleles in the ﬁrst phase and informative DQA1 and DRB1 alleles in the second
phase as previously described (13). ICA, IAA, GADA, and IA-2A were analyzed
as previously described (14).
Enterovirus RT-PCR. RNA was extracted from 140 l of serum or plasma
using a QIAamp viral RNA kit (Qiagen, Hilden, Germany). Screening for
enterovirus RNA was done by RT-PCR followed by hybridization of PCR
amplicons using an enterovirus-speciﬁc probe. The detection limit for the
method is 0.015 fg RNA, which is equivalent to fewer than four copies of
enteroviral RNA genome (15). All RNA-positive samples were retested twice,
and a result of at least two positive tests out of three tests was interpreted as
a positive sample.
Statistical analyses. The signiﬁcance of difference in the number of entero-
virus infections between case and control children was tested using condi-
tional logistic regression analysis (STATA statistical software, College Station,
TX). To adjust for more frequent sample collection from autoantibody-
positive children than control children, conditional logistic regression analysis
was calculated as proportions (%) of positive samples. Effect of HLA type for
EV infections was evaluated using Mann Whitney test.
RESULTS
Enterovirus RNA was detected in 2.7% of serum samples
(36 of 1,326). In case children, a total of 5.1% of the
samples (17 of 333) were enterovirus RNA positive com-
pared with 1.9% (19 of 993) in control children (P  0.01)
(Fig. 1).
The frequency of enterovirus RNA positivity was
further analyzed during different stages of the preclini-
cal disease process. The frequency of enterovirus RNA
in the case children peaked during the 6-month period
before the appearance of the ﬁrst autoantibody when
15.2% of the samples from the case children and 3.3% of
the samples from the control children were positive
(odds ratio [OR] 7.7 [95% CI 1.9–31.5], P  0.004). The
lowest frequency of enterovirus RNA was observed
during the time period from birth to 6 months before the
autoantibody positivity when 2.4% of the samples were
positive among the case children and 0.7% in the control
group (OR 3.1 [95% CI 0.4–22.4], P  0.27). After
autoantibody seroconversion, 3.9 vs. 2.2% of the sam-
ples were enterovirus RNA positive, respectively (Table
1 and Fig. 1).
The risk effect of enterovirus RNA was stronger among
boys than in girls (Table 1). This was similarly seen in
infections occurring before and after autoantibody sero-
conversion. The highest risk was related to infections that
occurred in boys during the 6-month period prior to the
ﬁrst autoantibody-positive sample (OR 18.2 [95% CI 2.0–
164.5], P  0.01) (Table 1).
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FIG. 1. Enterovirus (EV) RNA positivity in serum samples during
different stages of the diabetic disease process. 6 month period prior
AAb, 6-month time window before autoantibody seroconversion; Aab-
T1D, period from autoantibody seroconversion to diagnosis of type 1
diabetes; birth-before 6 month period prior Aab, time from birth to 6
months before the seroconversion to positivity for the ﬁrst autoanti-
body; birth-T1D, time from birth to diagnosis of type 1 diabetes. A: the
whole cohort. B: boys. C: girls. f, case children; , control children.
The differences between case and control children were tested using
conditional logistic regression analysis (P values shown).
TABLE 1
Risk effect of the detection of enterovirus RNA in serum for later
development of clinical type 1 diabetes
Time period OR 95% CI P
Boys and girls
Birth-before Aab 6.2 1.8–21 0.004
Birth-before 6 month
period prior Aab 3.1 0.4–22.4 0.27
6 month period prior Aab 7.7 1.9–31.5 0.004
Boys
Birth-before Aab 18.8 2.2–163.7 0.008
Birth-before 6 month
period prior Aab 3.9 0.2–63.3 0.34
6 month period prior Aab 18.2 2.0–164.5 0.01
Girls
Birth-before Aab 2.6 0.5–12.3 0.24
Birth-before 6 month
period prior Aab 2.4 0.2–39.7 0.53
6 month period prior Aab 3.1 0.4–21.8 0.26
6 month period prior AAb, 6-month time window before autoanti-
body seroconversion; birth-before 6 month period prior Aab, time
from birth to 6 months before the seroconversion to positivity for the
ﬁrst autoantibody; birth-before Aab, time from birth to the serocon-
version to positivity for the ﬁrst autoantibody.
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enterovirus RNA in serum. In children who were younger
than 6 months of age, only 1.0% of the samples were
enterovirus RNA positive compared with 3.5% of samples
in 6- to 18-month-old children and 5.0% of the samples in
children aged 18–24 months. At the age of 2 years, the
frequency of virus-positive samples decreased to 4.3%; the
frequency decreased further to 2.0% in children older than
2 years. Case children had the ﬁrst enterovirus RNA
positivity earlier than control children (median 10 vs. 16
months, respectively) (Fig. 2A). The age when autoanti-
bodies were ﬁrst detected varied from 4 months to 3 years
and 5 months (median 12 months) (Fig. 2B.).
In three case children, more than one follow-up sample
was enterovirus RNA positive (two positive samples in one
child and three positive samples in two children). None of
these samples were consecutive, and there were virus-
negative samples in between the positive ones. Different
virus genotypes were present in repeatedly positive sam-
ples in each of these children.
More samples were enterovirus RNA positive in case
children with high-risk HLA DR3-DQ2/DR4-DQ8 genotype
than in children who carried moderate-risk genotypes with
the DR4-DQ8 haplotype (6.8 vs. 2.2%) (P  0.002).
DISCUSSION
In the present study, enterovirus RNA was detected in
serum long before the diagnosis of clinical type 1 diabetes.
The frequency of virus peaked during the 6-month window
that preceded the ﬁrst appearance of diabetes-associated
autoantibodies. This temporal relationship has also been
observed in our previous studies, suggesting that entero-
virus infections may play a role in the initiation of the
-cell–damaging process (8,11). Enterovirus RNA was also
more common in the case than in the control children after
the initial autoantibody seroconversion but was not de-
tected in samples taken close to the presentation of
diabetes. The absence of enterovirus RNA at the diagnosis
of diabetes is in contrast to the majority of the retrospec-
tive case-control studies where altogether an average of
31% of the patients and 6% of the control subjects have
been positive for enterovirus RNA (3). The controversy
might be due to methodological differences, e.g., the
sensitivity of the PCR applied or the type of samples
collected (16). On the other hand, it may also reﬂect a true
difference in enterovirus epidemiology. In fact, we have
previously observed that enterovirus infections are less
frequent in Finland compared with many other countries
(17,18). In any case, the present study emphasizes the
importance of those infections that occur during the early
stages of the diabetogenic pathway, possibly playing a role
in the initiation of the -cell–damaging process rather than
the later stages of the process.
As enterovirus viremia usually lasts for a maximum of 2
weeks, the number of enterovirus episodes is largely
underestimated if samples are collected at longer inter-
vals. Accordingly, we can estimate the true number of
enterovirus RNA–positive episodes (N of positive samples/
detection period covered by the collected samples  total
follow-up time), which would be 154 episodes in case and
254 in control children (mean 3.7 vs. 1.6 episodes per
child). However, it is also possible that the difference
between the case and control children reﬂects prolonged
enterovirus episodes in the case group.
Our previous studies among DIPP children suggest that
the detection of the ﬁrst diabetes-associated autoantibody
and enterovirus RNA in stools shows similar seasonal
variation (19). In the present study, the same seasonal
pattern was seen in the detection of enterovirus RNA in
serum (frequent in the autumn and winter). In addition,
viral RNA was most common in serum at the age when
autoantibodies were most frequently induced. Autoanti-
bodies became detectable soon after detection of entero-
virus RNA in the serum. In mouse models, this time
interval has also been short (20).
It has previously been shown that children are protected
against enterovirus infections by maternal antibodies and
that this protection is at least partly mediated by antibod-
ies in breast milk. In Finland, children are breastfed for an
average of 8 months (range 0.15–23months) (21). This may
explain partly the low frequency of viral RNA observed in
infants aged 6 months. Viral RNA was most frequent in
12- to 18-month-old children, suggesting that there is a
susceptibility period at that age.
Enterovirus persistence has been shown to play a role in
chronic cardiomyopathies, and it may also be involved in
type 1 diabetes (5,22,23). In the present study, no signs of
persistent systemic infection were seen; enterovirus ge-
nomes that were detected from repeatedly positive chil-
dren represented different viral genotypes. However, in
persisting infections, the virus replication can occur at a
very low level and the virus may not be detectable in
peripheral blood even though it may be present in the
pancreas or other organs (4,23–25).
The risk effect of enterovirus RNA on autoantibody
development was stronger among boys than among girls.
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FIG. 2. Age of the ﬁrst detection of enterovirus (EV) RNA (A) and
autoantibodies (B) in serum. f, case children; , control children.
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complications of enterovirus infections. The higher num-
ber of enterovirus RNA–positive samples in children with
the DR3-DQ2/DR4-DQ8 genotype merits further investiga-
tion to ﬁnd out whether this genotype is particularly
susceptible to diabetogenic effect enteroviruses.
In conclusion, the present study supports the hypothesis
that enteroviruses play a role in the pathogenesis of type 1
diabetes. The presence of virus in serum was shown to be
a risk factor for the development of -cell–speciﬁc auto-
immunity, which progress to clinical diabetes, especially
among boys.
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